Elanco Animal Health
ELAN | NYSE
$22.43
+$0.01 (+0.04%)
At close: Sep 21, 2026, 3:59 PM ET
$22.99
+$0.56 (+2.50%)
Pre-market:
Sep 22, 2026, 4:00 AM ET
Company Profile
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Key Executives
| Name | Position |
|---|---|
| Jeffrey N. Simmons | President, Chief Executive Officer & Director |
| Robert VanHimbergen | Executive Vice President & Chief Financial Officer |
| David S. Kinard | Executive Vice President of Human Resources, Corporate Communications & Administration |
| Ellen de Brabander | Executive Vice President of Research, Development & Regulatory Affairs |
| James Meer | Senior Vice President & Chief Accounting Officer |
| Larbi Van Lier | Senior Vice President of Asia |
| Ramiro Martin Cabral | Executive Vice President & President of Elanco International |
| Shiv O'Neill | Executive Vice President, General Counsel & Corporate Secretary |
| Tiffany Ann Kanaga | Vice President of Investor Relations & ESG |
| Timothy J. Bettington | Executive Vice President of Center of Strategic Growth |
Elanco Animal Health
| Country | United States |
| IPO Date | Sep 19, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 9,650 |
| CEO | Jeffrey N. Simmons |
Contact Details
450 Elanco Circle Indianapolis,
Indiana 46221 United States
Stock Details
| Ticker Symbol | ELAN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001739104 |
| CUSIP Number | 28414H103 |
| ISIN Number | US28414H1032 |
| SIC Code | 2834 |
Recent News
- 6 days ago / seekingalpha.comElanco Animal Health Incorporated (ELAN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 7 days ago / prnewswire.comExpanding Tick and Itch Season Supports Momentum in Elanco Innovation, Meeting Pet Owner Demand for Health and Wellness Care
- 11 days ago / prnewswire.comElanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement
- 18 days ago / fool.comElanco Director Purchases 40,000 Shares for $936,000
- 27 days ago / prnewswire.comElanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility
- 1 month ago / seekingalpha.comElanco Animal Health: New Products To Support Growth
- 1 month ago / fool.comDirector's Confidence Visible as Elanco Leader Buys 10,000 Shares
- 1 month ago / seekingalpha.comElanco: Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform
- 2 months ago / gurufocus.comElanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livest
- 2 months ago / prnewswire.comElanco's CLiK™ Extra (dicyclanil topical suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Species
Add to Watchlist
Select watchlists to add or remove ELAN